Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call

Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) plans to release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time to review results and provide operational updates.

Participants can join the investor call by dialing (800) 717-1738 in the U.S. or (646) 307-1865 internationally. A replay will be available until Friday, August 28, 2026 at (844) 512-2921 or (412) 317-6671 (passcode 1174558). A live webcast and 30-day archive will be accessible at https://vivos.com/investors/. Vivos is a medical technology and healthcare services company focused on FDA-cleared diagnostic and treatment devices for obstructive sleep apnea and related breathing disorders in adults and children.

Market Context

Tag-specific history showed an average -1.06% move for comparable scheduling events. Recent insider ...

Analysis

Tag-specific history showed an average -1.06% move for comparable scheduling events. Recent insider records showed Net Buying totaling 5,498,660 shares. Moderate short positioning remained a volatility risk to monitor.

Key Figures

Reporting period: Q2 2026 Release date: August 14, 2026 Conference call time: 5:00 pm ET +5 more

8 metrics

Reporting period Q2 2026 Financial results scheduled for release

Release date August 14, 2026 After market close

Conference call time 5:00 pm ET Results review and operational updates

Affected adults Over 1 billion adults OSA and insomnia population aged 30-69 worldwide

Undiagnosed population 80% or more Adults with OSA and insomnia remain undiagnosed and unaware

FDA clearance 510(k) CARE devices described as FDA-cleared technology

Adult age range 30-69 years old Population affected by OSA and insomnia

Pediatric age range Ages 6 to 17 Children covered by stated FDA clearance

Previous Conferences,earnings date Reports

5 past events · Latest: Apr 15 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 15	Full-year results call	Neutral	+8.9%	Full-year 2025 results release and conference call were scheduled after market close.
Nov 19	Q3 results call	Neutral	-4.5%	Third-quarter 2025 results release and conference call were scheduled for the same day.
Aug 19	Q2 results call	Neutral	-4.0%	Second-quarter 2025 results release and conference call were scheduled after market close.
May 14	Q1 results call	Neutral	-3.2%	First-quarter 2025 results release and conference call were scheduled for the following day.
Mar 28	Full-year results call	Neutral	-2.5%	Full-year 2024 results release and conference call were scheduled after market close.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Comparable scheduling announcements produced four negative reactions and one positive reaction, with an average move of -1.06%.

Key Terms

osa, 510(k), cash burn, cpap

4 terms

osa medical

"patients suffering from obstructive sleep apnea (“OSA”)"

Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.

510(k) regulatory

"the only FDA 510(k) cleared technology"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

cash burn financial

"their anticipated effect on near-term revenue growth and cash burn"

Cash burn is the speed at which a company uses its available cash to pay for day‑to‑day operations, development and other outflows, usually expressed over a month or year. Investors care because it acts like a car’s fuel gauge: a high burn rate relative to cash on hand means the business may soon need extra financing or cut spending, while a low burn rate suggests greater financial stability and more time to grow.

cpap medical

"legacy OSA treatments like CPAP are often mechanistic"

A CPAP (continuous positive airway pressure) device is a machine that gently blows a steady stream of air through a mask to keep a person’s breathing passages open during sleep, commonly used to treat sleep apnea. For investors, CPAPs matter because they represent a medical-device market with recurring sales of equipment and disposable supplies, subject to safety reviews, insurance reimbursement rules and regulatory approvals that can affect a maker’s revenue and reputation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Call scheduled for today, Friday, August 14, 2026, at 5:00 pm ET

LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, announced it plans to release its second quarter 2026 financial results after market close today, Friday, August 14, 2026. The Company will conduct a conference call at 5:00 pm (Eastern Time) to review the results and provide operational updates.

Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management will discuss further details on topics including Vivos’ strategic collaborations and their anticipated effect on near-term revenue growth and cash burn.

To access Vivos’ investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the replay is 1174558. The replay will be available until Friday, August 28, 2026.

A live webcast of the conference call is available on Vivos’ website at https://vivos.com/investors/. An online archive of the webcast will be available on the Company’s website for 30 days following the call.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the flagship DNA appliance is the first to receive clearance for treating moderate to severe OSA in children. 

OSA and insomnia affect over 1 billion adults aged 30-69 years old worldwide, yet 80% or more remain undiagnosed and unaware of their condition. These chronic disorders are not just a sleep issue—they are closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes. Vivos CARE oral medical devices target the underlying physiology and anatomical deficiencies that are often associated with OSA.

Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.

Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com.

Cautionary Note Regarding Forward‑Looking Statements

This press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal” and variations of such words and similar expressions are intended to identify forward-looking statements.

These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos' control. Actual results (including the actual benefits of the Company’s new model described herein and actual revenue and cash flow results) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing due to, among other things, a deficiency in its stockholders’ equity; (v) market and other conditions, and (vi) other risk factors described in Vivos’ filings with the SEC. Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov.

Except to the extent required by law, Vivos expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any such statement is based.

Vivos Investor Relations Contact:

Jennifer Hauser, Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125

FAQ

When will Vivos Therapeutics (NASDAQ: VVOS) release its Q2 2026 financial results?

Vivos Therapeutics plans to release its Q2 2026 financial results after market close on Friday, August 14, 2026. According to Vivos, management will then host a conference call at 5:00 p.m. Eastern Time to review results and provide operational updates for investors.

How can investors join the Vivos Therapeutics (VVOS) Q2 2026 earnings conference call on August 14, 2026?

Investors can join the Vivos Q2 2026 call by dialing (800) 717-1738 in the U.S. or (646) 307-1865 internationally. According to Vivos, the conference call starts at 5:00 p.m. Eastern Time and will cover financial results and operational updates.

Is there a replay available for the Vivos Therapeutics (VVOS) Q2 2026 earnings call and how long will it last?

Yes, a replay of the Vivos Q2 2026 earnings call will be available until Friday, August 28, 2026. According to Vivos, U.S. callers can dial (844) 512-2921 and international callers (412) 317-6671, using replay passcode 1174558 to access the recording.

Will Vivos Therapeutics (VVOS) provide a webcast for the Q2 2026 earnings conference call?

Vivos will provide a live webcast of its Q2 2026 earnings call on the investors section of https://vivos.com/investors/. According to Vivos, an online archive of the webcast will remain available on the company’s website for 30 days following the call.

What topics will Vivos Therapeutics (VVOS) management discuss on the Q2 2026 earnings call?

Management plans to review Q2 2026 financial results and provide operational updates. According to Vivos, the call will also discuss its strategic collaborations and their anticipated effect on near-term revenue growth and company cash burn, offering investors additional business context.

What does Vivos Therapeutics (NASDAQ: VVOS) do in the sleep apnea treatment market?

Vivos Therapeutics is a medical technology and healthcare services company focused on diagnostic and treatment solutions for obstructive sleep apnea and related breathing disorders. According to Vivos, its FDA-cleared CARE oral devices and protocols, known as The Vivos Method, offer nonsurgical, noninvasive treatment options.